Generic placeholder image

Recent Patents on Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 1872-213X
ISSN (Online): 2212-2710

Daclizumab: A Potential Asthma Therapy?

Author(s): Sabina A. Antoniu

Volume 4, Issue 3, 2010

Page: [214 - 221] Pages: 8

DOI: 10.2174/187221310793564254

Price: $65

Abstract

Airways inflammation in asthma is triggered and maintained by CD4+ (Th2) cells which are activated by IL-2 and stimulate the eosinophilic inflammation, IgE secretion and mucus hyperproduction. Current anti-inflammatory therapies include inhaled corticosteroids, and leukotriene modifiers but they are not universally effective. IL-2 pathway inhibition might represent a potent anti-inflammatory therapy in asthma given the cytokine early role in the asthma complex inflammatory cascade and daclizumab which is a IL-2R blocker currently used as an immunsupressor in organ transplantation might be a potential asthma therapy. This is a review on the pathogenic role of IL-2, on the therapeutic potential of daclizumab and on its related patents.

Keywords: CD25, subunit-IL-2 receptor, CD4+ activation, daclizumab, asthma


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy